Lee Financial Co Buys New Stake in Iterum Therapeutics plc (NASDAQ:ITRM)

Lee Financial Co purchased a new stake in Iterum Therapeutics plc (NASDAQ:ITRM) during the 4th quarter, HoldingsChannel.com reports. The institutional investor purchased 16,000 shares of the company’s stock, valued at approximately $28,000.

Separately, Apollon Financial LLC raised its position in Iterum Therapeutics by 11.3% during the fourth quarter. Apollon Financial LLC now owns 250,250 shares of the company’s stock valued at $443,000 after acquiring an additional 25,500 shares in the last quarter. Hedge funds and other institutional investors own 9.21% of the company’s stock.

Iterum Therapeutics Trading Up 2.7 %

Shares of NASDAQ:ITRM opened at $1.54 on Friday. Iterum Therapeutics plc has a 12-month low of $0.81 and a 12-month high of $3.02. The business has a 50 day moving average of $1.70 and a two-hundred day moving average of $1.44. The company has a market capitalization of $42.38 million, a PE ratio of -0.77 and a beta of 2.28.

Iterum Therapeutics Company Profile

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.